Citrullinemia type 1 (CTLN1) is a urea cycle disorder (UCD) caused by mutations of the ASS1 gene, which is responsible for production of the enzyme argininosuccinate synthetase (ASS), and classically presented as life-threatening hyperammonemia in newborns. Therapeutic options are limited, and neurological sequelae may persist. To understand the pathophysiology and find novel treatments, induced pluripotent stem cells (iPSCs) were generated from a CTLN1 patient and differentiated into hepatocyte-like cells (HLCs). CTLN1-HLCs have lower ureagenesis, recapitulating part of the patient's phenotype. L-arginine, an amino acid clinically used for UCD treatment, improved this phenotype in vitro. Metabolome analysis revealed an increase in tricarboxylic acid (TCA) cycle metabolites in CTLN1, suggesting a connection between CTLN1 and the TCA cycle. This CTLN1-iPSC model improves the understanding of CTLN1 pathophysiology and can be used to pursue new therapeutic approaches.
Introduction
Citrullinemia type 1 (CTLN1) is an autosomal recessive urea cycle disorder (UCD) caused by the deficiency of argininosuccinate synthetase (ASS), a urea cycle enzyme responsible for the ATPdependent conversion of citrulline and aspartate into argininosuccinate. The responsible gene is ASS1, localized in chromosome 9q34.1, with an estimated disease incidence of 1:250,000. ASS is mainly produced in periportal hepatocytes, and its deficiency results in accumulation of citrulline and ammonia, leading to hyperammonemic encephalopathy, which can be fatal in the neonatal period or during episodes of metabolic burden such as pregnancy [1e3] . Treatments with amino acids such as Learginine, nitrogen scavengers such as benzoate and phenylacetate, protein restriction and if necessary, hemodialysis, have improved the survival up to 84%, however, almost half of the patients develop neurological disability in consequence of repeated episodes of hyperammonemia. Liver transplantation is the only curative treatment, but established neurological sequelae may remain [4e7] .
Although CTLN1 animal models have indicated gene therapy can improve specific phenotypes [8e10], a clinical trial for another UCD had fatal outcome, halting the clinical application of gene therapy [11] . Moreover, differences in ammonia metabolism between species hinder understanding of the pathophysiology and development of new treatments [12] .
Human induced pluripotent stem cells (iPSCs) are promising, since they can multiply indefinitely and differentiate into specific cell lineages [13, 14] . Hepatocyte-like cells (HLCs) differentiated from iPSCs have been used to model several liver-related diseases, including a1-antitrypsin deficiency and citrin-deficiency (CD), clarifying the pathophysiology to pursue new medical strategies [15e18] .
In this study, we generated an in vitro iPSC model of CTLN1 that partially reproduces the phenotype of the ammonia metabolism defect. We also analyzed the effect of L-arginine, which is commonly used to control the hyperammonemia of UCD patients. This model gives new insights on the pathophysiology and discovery of treatments for CTLN1 and other UCDs.
Materials and methods

Generation of iPSCs
Blood samples were taken from a CTLN1 patient to generate iPSCs. Informed consent was obtained in accordance with the Institutional Review Board. Peripheral mononuclear cells (PMNCs) were reprogrammed into iPSCs as described previously [14] . Briefly, a combination of episomal vectors encoding OCT4, SOX2, KLF4, L-MYC, LIN28 and p53 shRNA were transfected by electroporation into the PMNCs, and the cells were cultured on mitomycin C (Wako, Osaka, Japan)-treated SNL feeder cells. After 16e25 days, iPSC colonies were selected and expanded. These cells were maintained with Primate ES medium (ReproCELL, Tokyo, Japan) complemented with 4 ng/ml fibroblast growth factor 2 (FGF2, Wako) and 500 U/ml of penicillin and streptomycin (P/S, Thermo Fisher Scientific, Massachusetts, USA).
To obtain feeder-free iPSCs, we enzymatically removed SNL cells with CTK solution (0.1% collagenase type IV (Worthington Biochemical Corporation, New Jersey, USA), 0.25% trypsin (Thermo Fisher Scientific), 0.01 M CaCl 2 and 20% knockout serum replacement (KSR, Thermo Fisher Scientific)), detached the iPSCs with Accutase (Innovative Cell Technologies, California, USA) and pipetted them to obtain single cells. Cells were seeded at 5 Â 10 4 cells/well in 6-well plates (CellBIND; Corning, New York, USA) coated with Synthemax (Corning) and maintained with Essential 8 medium (Thermo Fisher Scientific) complemented by 1 mM of Y-27632 (Wako) for one day. Medium was changed daily, and passage was performed when colonies achieved 80e90% confluency.
Mutational analysis
Genomic DNA was isolated from fresh iPSC samples by Cell Lysis Solution (Qiagen, Hilden, Germany) and Protein Precipitation Solution (Qiagen) according to manufacturer's instructions. Primer pairs used to analyze ASS1 mutations were: 5 0 -CCTA-CACTGCATGACCTCAC-3 0 and 5 0 -GAAGAAAGTGTGTCCCCTGG-3 0 for Exon 6 and 5 0 -CTTGTCTCCTGTCAGACGAC-3 0 and 5 0 -CTCA-CATGAGGATGGCAGTG-3 0 for Exon 13. PCR was performed using KOD FX Neo (Toyobo, Osaka, Japan) in a Gene Amp PCR System 9700 (Thermo Fisher Scientific) with the next conditions: 1 cycle of 94 C for 2 min and 35 cycles of 10 s at 98 C, 30 s at 50 C and 30 s at 68 C. PCR products were sequenced by Sanger method on an automated DNA sequencer (3500xL Genetic Analyzer, Applied Biosystems, Thermo Fisher Scientific) using BigDye Xterminator Purification Kit (Thermo Fisher Scientific), according to the manufacturer's instructions [1, 2] .
Karyotyping
Chromosomal G-band analyses of CTLN1-iPSCs were performed by Nihon Gene Research Laboratories (Miyagi, Japan).
Embryoid body (EB) formation
iPSCs cultured on 10 cm dish were scraped off, dissociated in Primate ES medium and distributed into low attachment 6-well plates (Corning) for floating-culture with EB medium (Knockout DMEM (KO-DMEM), 20% KSR, 0.1 mM Non-essential amino acid solution (NEAA), 2 mM L-glutamine, 500 U/ml P/S and 0.5 mM 2-mercaptoethanol; all reagents from Thermo Fisher Scientific). On day 8, EBs were transferred into gelatin-coated 6-well plates and cultured with EB medium for another 8 days.
Teratoma formation
All animal experiments were approved by CiRA Animal Experiment Committee and performed in accordance with the institutional guidelines. iPSC colonies at 80e90% confluence in 10 cm dishes were harvested and centrifuged. Pellets were transplanted into testes of male 8-week-old NOD. CB17-Prkdc scid /L (NOD-SCID) mice (Charles River Laboratories Japan, Yokohama, Japan). Nine weeks after transplantation, teratomas were dissected from the mice, fixed in 4% paraformaldehyde (PFA; Nacalai Tesque, Kyoto, Japan) at 4 C overnight, washed thrice with PBS and maintained in 70% ethanol. Fixed teratomas were sectioned and stained with hematoxylin and eosin.
Differentiation into HLCs
Two CTLN1-iPSC lines (CTLN1A and CTLN1B) and two control lines (Control A (585A1) and Control B (201B6)) [13, 17] , approved by the Institutional Review Board, were used for hepatocyte differentiation. Previously reported step-wise protocols were adopted with some modifications [17, 18] . iPSCs at 80e90% confluence were enzymatically dissociated, pipetted to single cells with 0.5 mM EDTA/PBS followed by Accutase and cultured on Matrigel (BD Biosciences)-coated 12-well plates at a density of 1 Â 10 5 cells/cm 2 .
Step 1 (4 days): Cells were cultured with RPMI 1640 medium (Nacalai Tesque), 1 Â B27 (Thermo Fisher Scientific), 100 ng/ml Activin A (R&D Systems, Minneapolis, USA) and 500 U/ml P/S for four days, complemented with 3 mM CHIR99021 (Stemgent, Massachusetts, USA) for the first day and 1 mM for a subsequent two days, and 1 mM of Y-27632 for the first day.
Step 2 (7 days): Medium was changed to KO-DMEM complemented with 20% KSR, 1% DMSO (Sigma-Aldrich, Missouri, USA), 1% L-Glutamine, 1% NEAA, 0.2% 2-mercaptoethanol, 20 ng/ml recombinant human bone morphogenetic protein 4 (BMP4, Peprotech, New Jersey, USA) and 10 ng/ml FGF2.
Step 3 (7 days): Medium was changed to Hepatocyte Culture Medium (HCM, Lonza, Basel, Switzerland) complemented with 20 ng/ml of hepatocyte growth factor (HGF; Peprotech) and 20 ng/ ml Oncostatin M (OSM; Peprotech).
Functional assays
For indocyanine green (ICG) uptake, HLCs were incubated with 1 mg/ml ICG (Cardiogreen, Sigma-Aldrich) at 37 C for 60 min. Glycogen storage was evaluated by periodic acid-Schiff (PAS) staining kit (Sigma-Aldrich) according to the manufacturer's instructions. Low density lipoprotein (LDL) uptake was analyzed by incubating HLCs in 10 mg/ml of acetylated LDL labeled with 1,1'-dioctadecyl-3,3,3 0 ,3'-tetramethylindo-carbocyanine perchlorate (DiI-Ac-LDL, Alfa Aesar, Massachusetts, USA) with phenol red-free DMEM (Sigma-Aldrich) for 4 h at 37 C.
In order to concentrate live HLCs, LDL-stained cells were detached by Accumax (Innovative Cell Technologies), pipetted to single cells and sorted by a flow cytometer (BD FACS Aria II). Unstained cells were used to set the sorting gates [19] .
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was obtained by RNeasy kit (Qiagen), and cDNA was synthesized by ReverTra Ace (Toyobo). SYBR Green PCR Master Mix (Takara, Shiga, Japan) was used for qPCR. Reactions and analyses were performed by Step One Plus Real-Time PCR System (Thermo Fisher Scientific) in the next conditions: 95 C for 30 s, 40 cycles of 5 s at 95 C and 30 s at 60 C, and 1 cycle of 15 s at 95 C, 1 min at 60 C and 15 s at 95 C. The threshold cycle method was used to measure gene expression levels, which were normalized to the expression of a housekeeping gene, GAPDH. Primer pairs were: 5 0 -GAAGGTGAAGGTCGGAGTC-3 0 and 5 0 -GAAGATGGTGATGGGATTTC-3 0 for GAPDH, 5 0 -AGAACCTGTCACAAGCTGTG-3 0 and 5 0 -GACAG-CAAGCTGAGGATGTC-3 0 for AFP, 5 0 -CGCTATTAGTTCGTTACACCA-3 0 and 5 0 -TTTACAACATTTGCTGCCCA-3 0 for ALBUMIN (ALB) and 5 0 -TCGTGCATCCTCGTGTGGCTGAA-3 0 and 5 0 -CCA-CAAACTCCCTGCTGACATCC-3 0 for ASS1.
Immunocytochemistry
Cells were fixed with 4% PFA for 20 min at room temperature (RT) and washed thrice with PBS. Blocking was performed with 0.4% Triton X-100 (Nacalai Tesque) and 5% normal donkey or goat serum (Millipore, Massachusetts, USA) in PBS for 1 h at RT. Primary antibodies (Suppl. 
Metabolome analysis
Previously described methods were applied [20, 21] . Briefly, approximately 1 Â 10 6 differentiated cells cultured in 12-well (E) CTLN1A-iPSCs transplanted into immunodeficient mice developed teratomas containing tissues from three germ layers. Scale bars: 100 mm.
plates were washed twice with cold 5% mannitol, and 1 ml of icecold methanol with internal standards (25 mM each of L-methionine sulfone (Wako), 2-(n-morpholino) ethanesulfonic acid (Dojindo, Kumamoto, Japan) and D-camphor-10-sulfonic acid (Wako)) was applied for metabolome extraction. 400 ml of extract was mixed with water (200 ml) and chloroform (400 ml) and centrifuged (10,000 g, 3 min at 4 C). 400 ml of aqueous layer was filtered by HMT 5-kDa ultrafiltration tube (Ultrafree-MC-PLCC for Metabolome Analysis; Human Metabolome Technologies, Yamagata, Japan) to remove proteins and centrifuged (9,100 g, 3 h at 20 C). 320 ml of the filtrate was centrifugally concentrated for 2 h at 40 C (Refrigerated CentriVap Vacuum Concentrator, Labconco, Saitama, Japan). Product was dissolved in water (25 ml) containing 3-aminopyrrolidine (200 mM, Sigma-Aldrich) and trimesate (200 mM, Wako). Samples were dissolved in water (1:5) and capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS, Agilent Technologies, California, USA) was performed according to the methods described in the previous papers [20, 21] .
Statistical analyses
Statistical analyses were performed using GraphPad PRISM software version 7 (GraphPad Software Inc, California, USA). Student's t-test and two-and three-way analysis of variances (ANOVA) with Bonferroni post hoc test were used for assessment. P-values lower than 0.05 were considered significant.
Results and discussion
Generation of CTLN1-specific iPSCs
iPSCs were generated from a five-year old female CTLN1 patient with compound heterozygous mutations in the ASS1 gene (Exon 6, c.364-2 A > G, p. G259*; Exon 13, c.910 C > T, p. R304W) who presented neonatal hyperammonemia. The first mutation was described in a Turkish patient and the second mutation is present in 40% of Japanese CTLN1 patients [1, 2] . Twenty-two iPSC colonies exhibiting human embryonic stem cell-like morphology were cloned, nine confirmed silencing of episomal vectors by RT-PCR (data not shown), and two integration-free clones (CTLN1A and CTLN1B) were selected.
The sequence of CTLN1A-iPSCs confirmed ASS1 heterozygous mutations (Fig. 1A) and G-banding revealed normal karyotype (Fig. 1B, Suppl. Fig. 1A ). CTLN1-iPSCs were stained with pluripotency markers OCT4, NANOG, SSEA-4, TRA-1-60 and TRA-1-81, but not SSEA-1, which is specific for mouse (Fig. 1C, Suppl. Fig. 1B) . EB formation of CTLN1-iPSCs with ectoderm (TUJ1 (þ) neuronal cells), mesoderm (VIMENTIN (þ) mesenchymal cells) and endoderm (SOX17 (þ) definitive endoderm; Fig. 1D , Suppl. Fig. 1C ) and teratoma formation in immunodeficient NOD-SCID mouse that included ectoderm (neural rosette), mesoderm (cartilage) and endoderm (intestine; Fig. 1E , Suppl. Fig. 1D ) confirmed the multipotent differentiation capacity of CTLN1-iPSCs. 
Differentiation of CTLN1-iPSCs into HLCs
Two CTLN1-iPSC lines and two Control-iPSC lines were differentiated by a stepwise induction protocol into SOX17 (þ) definitive endoderm cells, AFP (þ) hepatoblast-like cells and ALB (þ) HLCs. The induction rate of ALB (þ) cells was similar among Control A (30.4 ± 4.9%), Control B (34.5 ± 9.9%), CTLN1A (34.7 ± 2.8%) and CTLN1B (38.4 ± 9.4%) (n ¼ 3; Fig. 2A, Suppl. Fig. 1E ). Functional analyses of hepatocytes showed ICG uptake, glycogen storage and LDL uptake in Control A-and CTLN1A-HLCs (Fig. 2B) . These results suggest that CTLN1-iPSCs can be differentiated into functional HLCs to a similar extent as Control-iPSCs.
Concentration of HLCs by flow cytometry
Since our protocol resulted in a low induction rate, we took advantage of the LDL uptake ability of hepatocytes to concentrate live HLCs by flow cytometry [19] . The LDL (þ) cell rate was 49.6 ± 2.7% for Control A, 36.4 ± 6.9% for Control B, 43.3 ± 6.0% for CTLN1A and 55.6 ± 7.1% for CTLN1B (n ¼ 3; Fig. 2C ). Higher prevalence of AFP (þ) or ALB (þ) cells in LDL (þ) cells than LDL (À) cells was observed (Fig. 2D, Suppl. Fig. 1F ). Higher expression levels of AFP (Fig. 2E) and ALB (Fig. 2F ) in LDL (þ) cells compared to LDL (À) cells, iPSCs or fetal liver by qRT-PCR confirmed the successful concentration of HLCs. ASS1 expression was also detected in Control A-and CTLN1A-LDL (þ) cells (Fig. 2G) . These results suggest that flow cytometry with LDL staining can be used to concentrate iPSCderived HLCs [19] .
Ureagenesis is decreased in CTLN1-HLCs
Deficiency of ASS is thought to cause an accumulation of ammonia and decrease of ureagenesis in CTLN1 patients (Fig. 3A ) [1, 2] . We performed an ammonia challenge assay to verify whether this phenotype can be reproduced in CTLN1-HLCs (Fig. 3B) . Sorted LDL (þ) cells were treated with 2 mM NH 4 Cl for 24 h, and supernatants were analyzed. Ammonia values were: 0.21 ± 0.04 pg/cell (Control A), 0.17 ± 0.02 pg/cell (Control B), 0.23 ± 0.00 pg/cell (CTLN1A) and 0.19 ± 0.04 pg/cell (CTLN1B) (n ¼ 3, Fig. 3C) . Urea values were: 1.16 ± 0.27 pg/cell (Control A), 0.85 ± 0.33 pg/cell (Control B), 0.70 ± 0.18 pg/cell (CTLN1A) and 0.50 ± 0.17 pg/cell (CTLN1B) (n ¼ 3, Fig. 3D ). There were no significant differences in ammonia and urea values between the two Control lines or between the two CTLN1 lines. Ammonia values did not significantly differ between the Control and CTLN1 groups, but ureagenesis was significantly less in the latter. One possible reason for not finding differences in ammonia values is that the ammonia assay is easily influenced by culture and sampling conditions, such as timing and temperature.
Ammonia clearance and ureagenesis improves with L-arginine treatment
L-arginine, an intermediary metabolite of the urea cycle (Fig. 3A) , is clinically used to control hyperammonemia in UCD patients [4, 5] . To examine the in vitro effect of L-arginine on LDL (þ) cells, we applied 10 mM L-arginine in the media containing 2 mM NH 4 Cl and cultured the cells for 24 h L-arginine treatment significantly decreased ammonia levels to 0.08 ± 0.04 pg/cell in Control A, 0.03 ± 0.02 pg/cell in Control B, 0.10 ± 0.03 pg/cell in CTLN1A and 0.07 ± 0.03 pg/cell in CTLN1B. Furthermore, it significantly increased urea levels to 3.67 ± 0.41 pg/cell in Control A, 4.05 ± 0.32 pg/cell in Control B, 2.15 ± 0.10 pg/cell in CTLN1A and 1.53 ± 0.40 pg/cell in CTLN1B (Fig. 3C and D) . No significant differences in Comparison of urea levels between Control and CTLN1 groups with or without L-arginine. Urea levels of CTLN1 group were lower than Control both with and without L-arginine. Larginine significantly improved ureagenesis in both groups, but more prominently in Control group (n ¼ 3, mean ± SE; n. s. not significant, **p < 0.01 and ****p < 0.001).
ammonia or urea levels between the two Control lines or the two CTLN1 lines after L-arginine treatment were found. L-arginine effectively diminished ammonia levels in both the Control and CTLN1 groups, without significant interaction of treatment effect with Control or CTLN1 groups (Fig. 3C) . For urea, the L-arginine's presence had significant effect in both Control and CTLN1 groups, but the effect of L-arginine was more pronounced for Control than for CTLN1 (Fig. 3D) . In contrast to the results for ammonia levels, there was a significant interaction effect between the treatment (presence or absence of L-arginine) and cell type (Control-or CTLN1-group) for urea levels.
Recently, a research group generated iPSCs from a patient with CD, which is another UCD that presents citrulline and ammonia accumulation similarly to CTLN1, but with a later and milder manifestation. They also reported the effect of L-arginine, but in contrast to our findings, there was only a slight improvement in ammonia and urea values. These differences might result from several factors, including the severity of CTLN1 phenotype compared to CD, use of cell sorting, and the different hepatocyte induction protocols and ammonia and urea assays used in the two studies [16] .
Most treatments for rare diseases such as CTLN1 are based on orphan drugs, since double blind controlled clinical trials are difficult for CTLN1 rarity and severity [4e6]. Our findings indicate that HLCs derived from CTLN1-iPSCs can be applied to evaluate the effectiveness of clinically-used drugs for UCDs and might be used to discover new drugs.
Tricarboxylic acid (TCA) cycle metabolites accumulate in CTLN1
Metabolome analyses of the differentiated Control A and CTLN1A cells were performed to evaluate the intracellular influence of ASS deficiency in the urea cycle and other metabolic pathways. We found no significant differences in urea cycle metabolites between Control A and CTLN1A cells, and citrulline values could not be detected (Fig. 4A) . Similar intracellular urea levels between Control A and CTLN1A were found in the metabolome assay, contrasting to results of the ammonia challenge. This inconsistency might be caused by the different sample materials (culture supernatant after 24 h-treatment for ammonia challenge vs. cell lysate at one time point for metabolome). Possible explanations for the conflicting findings of citrulline accumulation between clinical phenotype and this in vitro iPSC model include functional immaturity of the iPSC-derived HLCs and inadequate culture or assay conditions. Interestingly, we found that multiple TCA cycle-related metabolites, such as pyruvate, citrate, cis-aconitate, isocitrate, succinate, fumarate, malate and aspartate were significantly increased in CTLN1A-cells (Fig. 4B) , an effect that might be caused by a diversion of metabolic flux into TCA cycle due to blockage of the urea cycle by ASS dysfunction, since these two cycles are interconnected (Fig. 4C ). This result is consistent with a recent report that found TCA cycle adaptation with increased plasma citrate and a-ketoglutarate in CD pediatric patients [22] . Further studies should be performed to enhance the understanding of the relationship between CTLN1 and TCA-cycle findings.
In conclusion, we report a CTLN1-iPSC model that can be used as a platform to better understand the pathophysiology of CTLN1 and support the discovery of new therapeutic options. 
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